Quantcast

Latest Antibody-dependent cell-mediated cytotoxicity Stories

2014-05-29 04:22:19

BREDA, The Netherlands and GHENT, Belgium, May 29, 2014 /PRNewswire/ -- arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA). arGEN-X reported in December 2013 that this study met its translational development goals: all...

2012-10-11 04:04:09

Frozen, Thaw-and-Use Cells Reduce Variability Compared to PBMCs and NK Cells Madison, WI (PRWEB) October 10, 2012 Promega Corporation announces the introduction of a novel bioluminescent assay for the quantification of Fc effector function of antibody-based molecules in the development and manufacture of biologic drugs. The assay is ADCC mechanism of action (MOA)-based and features frozen, thaw-and-use effector cells, and optimized reagents and protocol to perform a reporter-based ADCC...

2010-06-23 05:00:00

PRINCETON, N.J., June 23 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline (GSK). BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). The second license agreement provides GSK...

2009-10-21 05:00:00

PRINCETON, N.J. and WALTHAM, Mass., Oct. 21 /PRNewswire/ -- BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. The agreement grants NKTT non-exclusive rights to research, develop, manufacture and commercialize antibodies targeting...

2009-10-05 16:00:00

PRINCETON, N.J., Oct. 5 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). BioWa's first Japanese pharmaceutical POTELLIGENT® License was initiated in May,...

2009-07-15 05:00:00

PRINCETON, N.J., July 15 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with Merck KGaA, Darmstadt, Germany, providing the global healthcare and chemicals company with access to BioWa's POTELLIGENT((R)) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC). "We are extremely pleased about our partnership with Merck KGaA, a global healthcare...

2008-12-08 05:00:00

PRINCETON, N.J., Dec. 8 /PRNewswire/ -- BioWa, Inc., announced today that it licensed to GlaxoSmithKline (NYSE: GSK) its POTELLIGENT(R) Technology for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity (ADCC). "GSK is recognized as a key player in the field of antibody drug discovery," said Dr. Masamichi Koike, BioWa President and CEO. "We believe this represents an important opportunity to promote the development...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'